Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK

BACKGROUND: The cost-effectiveness of umeclidinium bromide-vilanterol (UMEC/VI) versus tiotropium monotherapy in the UK was assessed using a UMEC/VI treatment-specific economic model based on a chronic obstructive pulmonary disease (COPD) disease-progression model. METHODS: The model was implemented...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cost Eff Resour Alloc
Autors principals: Punekar, Yogesh Suresh, Roberts, Graeme, Ismaila, Afisi, O’Leary, Martin
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2015
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4676898/
https://ncbi.nlm.nih.gov/pubmed/26692823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12962-015-0048-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars